Clinical Efficacy and Safety of Transurethral Plasma Enucleation in the Treatment of Benign Prostatic Hyperplasia

Abstract

Objective: This paper aims to analyze the effectiveness and safety of transurethral plasma enucleation in clinical treatment of benign prostatic hyperplasia. Methods: A total of 100 patients with benign prostatic hyperplasia who received surgical treatment in our hospital from January 2022 to January 2023 were randomly divided into groups by envelope method. 50 patients who received transurethral plasma resection of the prostate were selected as the control group and 50 patients who received transurethral plasma enucleation of the prostate were the study group. The effective rate of treatment, incidence of complications, postvoid residual (PVR) volume, maximum urinary flow rate (Qmax), and international prostate symptom score (I-PSS) were compared between the two groups. Results: By comparison, the effective rate of treatment in the study group was higher (P < 0.05). By comparison, the incidence of complications in the study group was lower (P < 0.05). Before treatment, there was no significant difference in PVR, Qmax, and I-PSS scores between the two groups (P > 0.05). After treatment, the PVR and I-PSS scores of the study group were lower, and Qmax was higher (P < 0.05). Conclusion: In the treatment of benign prostatic hyperplasia, the application of transurethral plasma enucleation can improve the clinical efficacy and clinical symptoms, with high safety and application value.